Dr. Reddy's Laboratories Allots 6,730 Equity Shares Following Stock Option Exercise
Dr. Reddy's Laboratories Limited announced the allotment of equity shares totaling 6,730 following the exercise of stock options under its employee schemes. The shares were allotted on June 19, 2026, and are fully paid up at a par value of Re. 1/- each.The allotment was made to eligible employees pursuant to the exercise of their Stock Options under two distinct plans: Dr. Reddy's Employees Stock Options Scheme, 2002, and Dr. Reddy's Employees ADR Stock Options Scheme, 2007.
This issuance contributes to the company’s total issued share capital as recorded on the allotment date. The details concerning the shares allotted and the resulting capital structure are provided below:
| Detail | Value |
|---|---|
| Date of Allotment/Issue | June 19, 2026 |
| Number of Shares Issued | 6,730 equity shares |
| Par Value per Share | Re. 1/- |
| Total Issues after this allotment | 83,46,76,800 shares |
| Total Issued Capital | Rs. 83,46,76,800 /- |
The issuance involved three distinct categories of employees, as detailed by the exercise price and premium:
| Shares Allotted | Exercise Price per Share | Premium per Share |
|---|---|---|
| 2,455 shares | Re.1/- | Nil premium |
| 2,000 shares | Rs. 562.80/- | Rs. 561.80/- |
| 2,275 shares | Rs. 735.80/- | Rs. 734.80/- |
The company confirmed that the newly allotted equity shares rank pari passu with all existing shares. Dr. Reddy's Laboratories Limited maintains a total of 83,46,76,800 issued shares and reports the total issued share capital at Rs. 83,46,76,800/- after this transaction.
DRREDDY Stock Price Movement
Dr. Reddy's Laboratories Limited shares are slipping by 0.20% in live trading as of 2:42 PM, currently finding trading levels at ₹1265 after shedding ₹2.50. The stock registers a volume of 362,578 shares traded so far in the ongoing session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.